Immunodetection of the Amyloid P Component in Alzheimer's Disease

Overview

Journal Acta Neuropathol

Specialty Neurology

Date 1989 Jan 1

PMID 2551124

Citations 24

Authors

T Duong

E C Pommier

A B SCHEIBEL

Affiliations

Soon will be listed here.

Abstract

Amyloid P component (AP), a plasma constituent normally not found in brain parenchyma, has been immunohistochemically determined in brains from patients with Alzheimer's disease (AD). Tissue came from 11 clinically diagnosed and neuropathologically verified AD patients and from 6 normal aged controls. Positive labeling for AP was observed in amyloidotic blood vessels, senile plaques (SP) and neurofibrillary tangles (NFT). The immunoreactivity was specific for these AD-associated lesions and clearly revealed their morphological appearance. Affected blood vessels appeared to be mainly of the arteriolar type and were labeled abluminally in short segments. SP constituents such as amyloid fibrils, amyloid core and degenerative axonal and dendritic processes were positive for AP antiserum; the morphology and distribution of immunoreactive SP corresponded to previous descriptions. Labeling of NFT revealed the morphology of paired helical and straight filaments. In all cerebral areas studied, tangle-bearing neurons were immunoreactive to AP antiserum, suggesting that AP is involved in early cellular development of NFT. Given the large molecular weight of AP (about 220,000), these results point to a potential impairment of the blood-brain barrier in AD. Since AP is always present in systemic amyloidosis, its detection in cerebral amyloidosis associated with AD may suggest mechanisms common to the two disorders.

Citing Articles

Dementia in the older population is associated with neocortex content of serum amyloid P component.

Ellmerich S, Taylor G, Richardson C, Minett T, Schmidt A, Brayne C Brain Commun. 2021; 3(4):fcab225.

PMID: 34671726 PMC: 8523881. DOI: 10.1093/braincomms/fcab225.

Extracellular protein components of amyloid plaques and their roles in Alzheimer's disease pathology.

Rahman M, Lendel C Mol Neurodegener. 2021; 16(1):59.

PMID: 34454574 PMC: 8400902. DOI: 10.1186/s13024-021-00465-0.

On the Role of Platelet-Generated Amyloid Beta Peptides in Certain Amyloidosis Health Complications.

Inyushin M, Zayas-Santiago A, Rojas L, Kucheryavykh L Front Immunol. 2020; 11:571083.

PMID: 33123145 PMC: 7567018. DOI: 10.3389/fimmu.2020.571083.

A Peptide Originated from Platelets Promises New Strategy in Anti-Alzheimer's Drug Development.

Inyushin M, Sanabria P, Rojas L, Kucheryavykh Y, Kucheryavykh L Biomed Res Int. 2017; 2017:3948360.

PMID: 29018812 PMC: 5605787. DOI: 10.1155/2017/3948360.

A wellness study of 108 individuals using personal, dense, dynamic data clouds.

Price N, Magis A, Earls J, Glusman G, Levy R, Lausted C Nat Biotechnol. 2017; 35(8):747-756.

PMID: 28714965 PMC: 5568837. DOI: 10.1038/nbt.3870.

References

Osmand A, Friedenson B, Gewurz H, Painter R, Hofmann T, Shelton E . Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc Natl Acad Sci U S A. 1977; 74(2):739-43. PMC: 392369. DOI: 10.1073/pnas.74.2.739. View

Coria F, Castano E, Prelli F, van Duinen S, Shelanski M, Frangione B . Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis. Lab Invest. 1988; 58(4):454-8. View

Khachaturian Z . Diagnosis of Alzheimer's disease. Arch Neurol. 1985; 42(11):1097-105. DOI: 10.1001/archneur.1985.04060100083029. View

Woo P, Korenberg J, WHITEHEAD A . Characterization of genomic and complementary DNA sequence of human C-reactive protein, and comparison with the complementary DNA sequence of serum amyloid P component. J Biol Chem. 1985; 260(24):13384-8. View

Duyckaerts C, Hauw J, Bastenaire F, Piette F, Poulain C, Rainsard V . Laminar distribution of neocortical senile plaques in senile dementia of the Alzheimer type. Acta Neuropathol. 1986; 70(3-4):249-56. DOI: 10.1007/BF00686079. View

Rowe I, Jensson O, Lewis P, Candy J, Tennent G, Pepys M . Immunohistochemical demonstration of amyloid P component in cerebro-vascular amyloidosis. Neuropathol Appl Neurobiol. 1984; 10(1):53-61. DOI: 10.1111/j.1365-2990.1984.tb00340.x. View

Kidd M, Allsop D, Landon M . Senile plaque amyloid, paired helical filaments, and cerebrovascular amyloid in Alzheimer's disease are all deposits of the same protein. Lancet. 1985; 1(8423):278. DOI: 10.1016/s0140-6736(85)91054-2. View

Elovaara I, Maury C, Palo J . Serum amyloid A protein, albumin and prealbumin in Alzheimer's disease and in demented patients with Down's syndrome. Acta Neurol Scand. 1986; 74(3):245-50. DOI: 10.1111/j.1600-0404.1986.tb07863.x. View

Saper C, German D, White 3rd C . Neuronal pathology in the nucleus basalis and associated cell groups in senile dementia of the Alzheimer's type: possible role in cell loss. Neurology. 1985; 35(8):1089-95. DOI: 10.1212/wnl.35.8.1089. View

10.

Baltz M, Caspi D, Evans D, Rowe I, Hind C, Pepys M . Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits. Clin Exp Immunol. 1986; 66(3):691-700. PMC: 1542455. View

11.

SCHEIBEL A, Duong T, Tomiyasu U . Denervation microangiopathy in senile dementia, Alzheimer type. Alzheimer Dis Assoc Disord. 1987; 1(1):19-37. DOI: 10.1097/00002093-198701000-00004. View

12.

Binette P, Binette M, CALKINS E . The isolation and identification of the P-component of normal human plasma proteins. Biochem J. 1974; 143(1):253-4. PMC: 1168374. DOI: 10.1042/bj1430253. View

13.

Iseki E, Amano N, Matsuishi T, Yokoi S, Arai N, Yagishita S . A case of familial, atypical Alzheimer's disease: immunohistochemical study of amyloid P-component. Neuropathol Appl Neurobiol. 1988; 14(2):169-74. DOI: 10.1111/j.1365-2990.1988.tb00878.x. View

14.

Prelli F, Pras M, Frangione B . The primary structure of human tissue amyloid P component from a patient with primary idiopathic amyloidosis. J Biol Chem. 1985; 260(24):12895-8. View

15.

Mann D, YATES P, Marcyniuk B . A comparison of changes in the nucleus basalis and locus caeruleus in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1984; 47(2):201-3. PMC: 1027693. DOI: 10.1136/jnnp.47.2.201. View

16.

Rogers J, Morrison J . Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer's disease. J Neurosci. 1985; 5(10):2801-8. PMC: 6565139. View

17.

Husebekk A, Skogen B, Husby G, Marhaug G . Transformation of amyloid precursor SAA to protein AA and incorporation in amyloid fibrils in vivo. Scand J Immunol. 1985; 21(3):283-7. DOI: 10.1111/j.1365-3083.1985.tb01431.x. View

18.

Westermark P, Shirahama T, Skinner M, Brun A, Cameron R, Cohen A . Immunohistochemical evidence for the lack of amyloid P component in some intracerebral amyloids. Lab Invest. 1982; 46(5):457-60. View

19.

Masters C, Beyreuther K . The blood-brain barrier in Alzheimer's disease and normal aging. Neurobiol Aging. 1988; 9(1):43-4. DOI: 10.1016/s0197-4580(88)80015-0. View

20.

Kirschner D, Abraham C, Selkoe D . X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-beta conformation. Proc Natl Acad Sci U S A. 1986; 83(2):503-7. PMC: 322888. DOI: 10.1073/pnas.83.2.503. View